Hepatocellular Carcinoma Clinical Trials in Dallas, Texas

7 studies are recruiting for hepatocellular carcinoma in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

   This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

   Locations

   8 in total

   Run by

   Eureka Therapeutics Inc.

   See if you can join NCT04864054 on ClinicalTrials.gov

2. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Dallas, Texas

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas, Texas

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

4. CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

   The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound fo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   2 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT06184152 on ClinicalTrials.gov

5. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

   The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

   Locations

   21 in total

   Run by

   Tvardi Therapeutics, Incorporated

   See if you can join NCT05440708 on ClinicalTrials.gov

6. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

   Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Texas Oncology - Dallas - Worth Street /ID# 265806, Dallas, Texas

   Locations

   37 in total

   Run by

   AbbVie

   See if you can join NCT06109272 on ClinicalTrials.gov

7. Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

   This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 881, Dallas, Texas

   Locations

   32 in total

   Run by

   Can-Fite BioPharma

   See if you can join NCT05201404 on ClinicalTrials.gov